A trial of intranasal Atrovent versus placebo in the treatment of vasomotor rhinitis.
Twenty-six patients with perennial rhinorrhea were treated by Atrovent, the anticholinergic agent, or placebo in a randomized double-blind crossover trial. The severity and duration of rhinorrhea were significantly reduced by Atrovent. Local side effects were more frequent with the active drug. These were reduced in a later open trial by a reduction in dosage.
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D001286:Atropine Derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012223:Rhinitis, Vasomotor / Q000188:drug therapy*
D001286:Atropine Derivatives; D009241:Ipratropium